JAZZ PHARMACEUTICALS FRANCE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Phase 2
Withdrawn
- Conditions
- Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02150928
- Locations
- 🇪🇸
Hospital of Navarra, Pamplona, Navarra, Spain
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Phase 3
Completed
- Conditions
- EpilepsyDravet Syndrome
- Interventions
- Drug: GWP42003-P 20 mg/kg/day DoseDrug: Placebo control
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02091375
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
Phase 2
Completed
- Conditions
- EpilepsyDravet Syndrome
- Interventions
- Drug: GWP42003-P 5 mg/kg/day DoseDrug: GWP42003-P 10 mg/kg/day DoseDrug: GWP42003-P 20 mg/kg/day DoseDrug: Placebo control
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT02091206
An Observational Post-Marketing Safety Registry of Sativex®
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 978
- Registration Number
- NCT02073474
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 207
- Registration Number
- NCT02053272
- Locations
- 🇬🇧
Churchill Hospital, Oxford, Oxfordshire, United Kingdom
🇬🇧Hathaway Surgery, Chippenham, Wiltshire, United Kingdom
🇷🇴Nicodiab SRL, Bucuresti, Romania
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Phase 2
Completed
- Conditions
- SchizophreniaSchizophrenia-related Psychotic Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02006628
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT01964547
- Locations
- 🇨🇿
MS Centre, Charles University, Prague, Czechia
A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT01918735
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01898520
- Locations
- 🇬🇧
Center 1, London, United Kingdom
🇬🇧Center 6, Cambridge, United Kingdom
🇨🇿Center 14, Prague, Czechia
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT01888120
- Locations
- 🇺🇸
Clearwater Pain Management, Clearwater, Florida, United States
🇺🇸Integrated Pain Solutions, Columbus, Ohio, United States
🇺🇸Desert Pain Institute, Mesa, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath